Sleep extension and metabolic health in male overweight/obese short sleepers: A randomised controlled trial. (29th August 2021)

• Record Type: Journal Article
• Authors: Hartescu, Iuliana; Stensel, David J.; Thackray, Alice E.; King, James A.; Dorling, James L.; Rogers, Eva N.; Hall, Andrew P.; Brady, Emer M.; Davies, Melanie J.; Yates, Thomas; Morgan, Kevin
• Is Part Of: Journal of sleep research. Volume 31:Number 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-08-29
• Subjects: cardiovascular health -- insufficient sleep -- metabolic health -- short sleep duration; Sleep -- Periodicals; Sleep disorders -- Periodicals; 612.821
• DOI: 10.1111/jsr.13469
• Languages: English
• ISSNs: 0962-1105

Abstract

Summary: While limited evidence suggests that longer sleep durations can improve metabolic health in habitual short sleepers, there is no consensus on how sustained sleep extension can be achieved. A total of 18 men (mean [ SD ] age 41 [ 9] years), who were overweight/obese (mean [ SD ] body mass index 30 [3] kg/m 2 ) and short sleepers at increased risk of type 2 diabetes were randomised to a 6‐week sleep‐extension programme based on cognitive behavioural principles ( n = 10) or a control ( n = 8) group. The primary outcome was 6‐week change in actigraphic total sleep time (TST). Fasting plasma insulin, insulin resistance (Homeostatic Model Assessment for Insulin Resistance [HOMA‐IR]), blood pressure, appetite‐related hormones from a mixed‐meal tolerance test, and continuous glucose levels were also measured. Baseline to 6‐week change in TST was greater in the sleep‐extension group, at 79 (95% confidence interval [CI] 68.90, 88.05) versus 6 (95% CI −4.43, 16.99) min. Change in the sleep‐extension and control groups respectively also showed: lower fasting insulin (−11.03 [95% CI −22.70, 0.65] versus 7.07 [95% CI −4.60, 18.74] pmol/L); lower systolic (−11.09 [95% CI −17.49, −4.69] versus 0.76 [95% CI −5.64, 7.15] mmHg) and diastolic blood pressure (−12.16 [95% CI −17.74, −6.59] versus 1.38 [95% CI −4.19, 6.96] mmHg); lower mean amplitude of glucose excursions (0.34 [95% CI −0.57, −0.12] versus 0.05 [95% CI −0.20, 0.30] mmol/L); lower fasting peptide YY levels (−18.25 [95%CI −41.90, 5.41] versus 21.88 [95% CI −1.78, 45.53] pg/ml), and improved HOMA‐IR (−0.51 [95% CI −0.98, −0.03] versus 0.28 [95% CI −0.20, 0.76]). Our protocol increased TST and improved markers of metabolic health in male overweight/obese short sleepers.